6. 2012: 劉侶 旅亮流 留旅慮亮凌 留慮竜僚ホ/ 虜劉僚凌
35
25
20
15
10
5
0
30
Phase I
Phase II
Phase III
Phase IV
5
16
33
29
29
6 9 9
2010
2012
裡亮劉留亮留 (2010-2012):
竜旅凌旅亮 凌僚 留旅慮亮 留慮竜僚ホ/虜劉僚凌
7. 2012: 劉侶 旅亮流 凌 凌凌了凌粒旅亮凌
300000
200000
100000
0
400000
Phase I
Phase II
Phase III
Phase IV
0
367.563
306.567
234.515
115.540
172.191
251.899
195.350
2010
2012
裡亮劉留亮留 (2010-2012):
竜溜侶 凌僚 凌凌了凌粒旅亮 留 296 竜 218K 竜
8. Hospital IEC*
1. Approval OR
2. Objections to NEC
within 30 days of
file receipt
Hospital IEC
Hospital
IEC
500
Hospital 2
Investigator/Site
Submission
Hospital 1
CTA
Step 1
*Approval window: 0-30 days
Silent approval if no response
Step 2
Approval window: 1 month**
Approval
CTA
4 Parties
Clinical Trial
Agreement
Review/Sign
CTA
CTA
YPE/Research Committee
OR
University/Research
Committee
YPE/Research Committee
OR
University/Research Committee
Company
HA/F
NEC
Submission
**
In parallel
Day 0 (study file receipt)
Day 30
Hospital Dir.
Signs or
rejects within
5 days of
IRB/IECs
approval
Within 5 days
To
ELKE/ELKEA
Sign within
10 days
since Hosp.
Dir.
signature
notify
Approved/rejected
In case of NIS, the
timeframe for final
signatures by ELKE/ELKEA
is 30 days since the
IRB/IEC approval
500
250
離凌粒旅虜流 留留侶 / 了旅僚旅虜劉 竜了劉竜
(離39(留)/凌旅虜.18910/21.2.2013 )
凌硫了竜亮竜僚侶 隆旅略虜竜旅留 侶 隆旅留隆旅虜留溜留
凌粒留流 竜 45 侶亮劉竜 亮竜 留略了了侶了侶
劉粒虜旅侶 &陸 竜 60 侶亮劉竜
13. 留留僚凌亮流 了旅僚旅虜ホ 竜了竜ホ マ侶
50.124 registered studies
Start Date in
2012
Start Date in
2013
10146 9041
EOF Data* on New Studies Submitted
In 2012 In 2013
138 122
陸-旅凌旅虜侶旅虜凌溜 劉了竜粒凌旅: 404
(05/2010-06/2013)
*data is based on new studies submitted for approval
per annum-verbal communication
Source: clinicaltrials.gov 07Dec2014
14. 留留僚凌亮流 了旅僚旅虜ホ 竜了竜ホ マ侶
14000 Germany
12328
11523
10000
9874
0
2000
4000
6000
8000
7318
6832
5794
5537
4669
3867
3762
3754
3306
2685
2457
2444
1949
1681
1640
1158
1134
1097
941
639
608
601
597
550
391
107
96
92
76
21
12
12000
France
United Kingdom
Italy
Spain
Netherlands
Belgium
Denmark
Poland
Switzerland
Sweden
Austria
Czech Republic
Norway
Hungary
Finland
Greece
Romania
Slovakia
Portugal
Bulgaria
Ireland
Croatia
Lithuania
Serbia
Estonia
Latvia
Slovenia
Bosnia and Herzegovina
Iceland
Fyrom
Luxembourg
Albania
Montenegro
Greece 176 131
Source: clinicaltrials.gov 07Dec2014
Countries Start Date in
2012
Start Date in
2013
Belgium 565 553
Czech Republic 287 260